Pacylex Pharmaceuticals, Inc.
Most Innovative BioTech Oncology Company 2024 - Canada
Pacylex’s zelenirstat is an oral, broad-spectrum, first-in-class drug that selectively affects cancers by inhibiting myristoylation. It prevents membrane attachment of proteins essential for cancer cell growth, proliferation, energy, and survival.
Zelenirstat was well-tolerated in Phase 1 patients. Two Phase 2a studies are underway at a dose that delivered stable disease to 57% of Phase 1 patients, and zelenirstat received Orphan Drug and Fast Track designations for acute myeloid leukemia.
Visit Site